Lantern Pharma (LTRN) Competitors $3.15 0.00 (0.00%) As of 09:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LTRN vs. FATE, KYTX, BDTX, VXRT, LXEO, LYEL, BYSI, NMRA, NKTX, and FTLFShould you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Fate Therapeutics (FATE), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), Vaxart (VXRT), Lexeo Therapeutics (LXEO), Lyell Immunopharma (LYEL), BeyondSpring (BYSI), Neumora Therapeutics (NMRA), Nkarta (NKTX), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Lantern Pharma vs. Its Competitors Fate Therapeutics Kyverna Therapeutics Black Diamond Therapeutics Vaxart Lexeo Therapeutics Lyell Immunopharma BeyondSpring Neumora Therapeutics Nkarta FitLife Brands Lantern Pharma (NASDAQ:LTRN) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Which has higher valuation & earnings, LTRN or FATE? Lantern Pharma has higher earnings, but lower revenue than Fate Therapeutics. Lantern Pharma is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantern PharmaN/AN/A-$20.78M-$1.84-1.71Fate Therapeutics$13.63M9.96-$186.26M-$1.49-0.80 Do institutionals and insiders believe in LTRN or FATE? 28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 7.3% of Lantern Pharma shares are held by company insiders. Comparatively, 5.5% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is LTRN or FATE more profitable? Lantern Pharma has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Fate Therapeutics' return on equity of -47.17% beat Lantern Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Lantern PharmaN/A -83.26% -70.65% Fate Therapeutics -1,318.93%-47.17%-34.60% Do analysts prefer LTRN or FATE? Lantern Pharma presently has a consensus price target of $25.00, indicating a potential upside of 693.65%. Fate Therapeutics has a consensus price target of $3.83, indicating a potential upside of 223.49%. Given Lantern Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Lantern Pharma is more favorable than Fate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 Which has more risk & volatility, LTRN or FATE? Lantern Pharma has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Does the media favor LTRN or FATE? In the previous week, Fate Therapeutics had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for Fate Therapeutics and 1 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 1.89 beat Fate Therapeutics' score of 0.53 indicating that Lantern Pharma is being referred to more favorably in the media. Company Overall Sentiment Lantern Pharma Very Positive Fate Therapeutics Positive SummaryFate Therapeutics beats Lantern Pharma on 8 of the 14 factors compared between the two stocks. Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LTRN vs. The Competition Export to ExcelMetricLantern PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.90M$2.85B$5.48B$8.94BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-1.7121.1726.2219.74Price / SalesN/A262.85394.92109.12Price / CashN/A41.8936.4957.06Price / Book1.617.237.915.37Net Income-$20.78M-$55.05M$3.15B$248.34M7 Day Performance1.29%-0.60%0.75%1.67%1 Month Performance-1.25%3.77%3.46%4.56%1 Year Performance-28.41%2.20%34.60%18.42% Lantern Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LTRNLantern Pharma2.287 of 5 stars$3.15flat$25.00+693.7%-30.3%$33.90MN/A-1.7120Positive NewsGap DownFATEFate Therapeutics4.0733 of 5 stars$1.14-4.2%$3.83+236.3%-65.0%$136.38M$13.63M-0.77550Gap DownKYTXKyverna Therapeutics1.5834 of 5 stars$3.22+4.9%$18.50+474.5%-64.5%$132.68M$7.03M-0.9596BDTXBlack Diamond Therapeutics3.2188 of 5 stars$2.27-2.6%$14.60+543.2%-47.2%$132.49MN/A37.8390Positive NewsAnalyst ForecastVXRTVaxart2.3389 of 5 stars$0.56-3.4%$3.00+435.3%-33.2%$132.42M$28.70M-2.08120Positive NewsGap UpLXEOLexeo Therapeutics2.1492 of 5 stars$3.96+1.3%$16.60+319.2%-73.0%$129.80M$650K-1.2058LYELLyell Immunopharma3.2739 of 5 stars$8.99+3.5%$20.00+122.5%-70.2%$128.68M$60K-0.36270BYSIBeyondSpringN/A$2.74-13.6%N/A-2.0%$127.80M$1.75M0.0080High Trading VolumeNMRANeumora Therapeutics2.524 of 5 stars$0.75-5.1%$9.29+1,144.7%-92.0%$127.08MN/A-0.46108Positive NewsGap UpNKTXNkarta2.2414 of 5 stars$1.75-1.4%$14.33+721.4%-70.8%$125.60MN/A-1.16140News CoverageFTLFFitLife Brands4.375 of 5 stars$12.99-2.5%$20.50+57.8%-14.3%$125.09M$64.47M15.4620 Related Companies and Tools Related Companies FATE Alternatives KYTX Alternatives BDTX Alternatives VXRT Alternatives LXEO Alternatives LYEL Alternatives BYSI Alternatives NMRA Alternatives NKTX Alternatives FTLF Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LTRN) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LTRN Stock Alerts